Pharmaceutical formulations of HDAC inhibitors
This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
1. A pharmaceutical composition consisting essentially of:
(a) a histone deacetylase (HDAC) inhibitor; and,
(b) at least one basic in situ salt former, wherein the salt former is free arginine, meglumine or free meglumine, and, (c) a pharmaceutically acceptable excipient or carrier;
wherein said HDAC inhibitor is selected from compounds of the following formula and pharmaceutically acceptable salts thereof:
wherein:
A is a substituted or unsubstituted:
C 6-20 carboaryl, or
C 5-20 heteroaryl;
Q 1 is:
a covalent bond, or
a substituted or unsubstituted
C 1-7 alkylene,
C 2-7 alkenylene;
J is:
—NR N —S(═O) 2 —, or
—S(═O) 2 —NR N —;
R N is:
—H, or
a substituted or unsubstituted
C 1-7 alkyl,
C 3-20 heterocyclyl,
C 6-20 carboaryl,
C 5-20 heteroaryl,
C 6-20 carboaryl-C 1-7 alkyl, or
C 5-20 heteroaryl-C 1-7 alkyl;
Q 2 is a substituted or unsubstituted:
C 6-20 carboarylene,
C 5-20 heteroarylene,
C 6-20 carboarylene-C 1-7 alkylene,
C 5-20 heteroarylene-C 1-7 alkylene,
C 6-20 carboarylene-C 2-7 alkenylene,
C 5-20 heteroarylene-C 2-7 alkenylene,
C 1-7 alkylene-C 6-20 carboarylene,
C 1-7 alkylene-C 5-20 heteroarylene,
C 2-7 alkenylene-C 6-20 carboarylene,
C 2-7 alkenylene-C 5-20 heteroarylene,
C 1-7 alkylene-C 6-20 carboarylene-C 1-7 alkylene,
C 1-7 alkylene-C 5-20 heteroarylene-C 1-7 alkylene,
C 2-7 alkenylene-C 6-20 carboarylene-C 1-7 alkylene,
C 2-7 alkenylene-C 5-20 heteroarylene-C 1-7 alkylene,
C 1-7 alkylene-C 6-20 carboarylene-C 2-7 alkenylene,
C 1-7 alkylene-C 5-20 heteroarylene-C 2-7 alkenylene,
C 2-7 alkenylene-C 6-20 carboarylene-C 2-7 alkenylene, or
C 2-7 alkenylene-C 5-20 heteroarylene-C 2-7 alkenylene,
and is unsubstituted or substituted.
2. A pharmaceutical composition according to claim 1 , wherein the HDAC inhibitor is selected from the following compounds and pharmaceutically acceptable salts thereof:
3. A pharmaceutical composition according to claim 1 , wherein the HDAC inhibitor is selected from the following compound and pharmaceutically acceptable salts thereof:
4. A pharmaceutical composition according to claim 1 , wherein the HDAC inhibitor is:
5. A pharmaceutical composition according to claim 3 , further comprising meglumine.
6. A pharmaceutical composition according to claim 3 , wherein said free arginine is: free L-arginine.
7. A pharmaceutical composition according to claim 5 , wherein said meglumine is: free meglumine or a pharmaceutically acceptable salt of meglumine.
8. A pharmaceutical composition according to claim 3 , wherein the molar ratio of arginine to said HDAC inhibitor is at least 0.5 to 5.
9. A pharmaceutical composition according to claim 5 , wherein the molar ratio of meglumine to said HDAC inhibitor is at least 0.5 to 5.
10. A pharmaceutical composition according to claim 3 , which is a liquid.
11. A pharmaceutical composition according to claim 3 , which is an aqueous liquid.
12. A pharmaceutical composition according to claim 3 , wherein the pharmaceutically acceptable excipient or carrier is: water-for-injection, aqueous saline solution, aqueous glucose solution, saline for injection/infusion, glucose for injection/infusion, Ringer's solution, or lactated Ringer's solution.
13. A pharmaceutical composition according to claim 3 , wherein the pharmaceutically acceptable excipient or carrier is: aqueous saline solution or aqueous glucose solution.
14. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 0.1-1000 mg/mL.
15. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 30-300 mg/mL.
16. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 0.3-3000 mM.
17. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 100-500 mM.
18. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 0.01-300 mg/mL.
19. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 1.0-10 mg/mL.
20. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 0.01-100 mM.
21. A pharmaceutical composition according to claim 10 , which comprises said HDAC inhibitor at a concentration of 3-30 mM.
22. A pharmaceutical composition according to claim 10 , wherein said composition is suitable for parenteral administration to a patient.
23. A pharmaceutical composition according to claim 10 , wherein said composition is suitable for administration to a patient by injection.
24. A pharmaceutical composition according to claim 10 , wherein said composition is suitable for administration to a patient by infusion.
25. A pharmaceutical composition according to claim 3 , which is a solid.
26. A pharmaceutical composition according to claim 3 , which is in the form of a powder, granules, tablets, or a lyophilate/lyophilisate.
27. An intravenous (IV) infusion bag containing a pharmaceutical composition according to claim 10 .
28. A vial or ampoule containing a pharmaceutical composition according to claim 10 .
29. A kit comprising:
(a) a pharmaceutical composition according to claim 10 , provided in a suitable container with suitable packaging; and
(b) instructions for use.
30. An aqueous liquid pharmaceutical composition consisting essentially of:
(a) a histone deacetylase (HDAC) inhibitor; and,
(b) at least one basic in situ salt former, wherein the salt former is free arginine, meglumine or free meglumine, and, (c) a pharmaceutically acceptable excipient or carrier;
wherein said HDAC inhibitor is:
31. A composition according to claim 30 , which comprises said HDAC inhibitor at a concentration of about 50 mg/mL.
32. A composition according to claim 31 , wherein the molar ratio of said L-arginine to said HDAC inhibitor is from 0.8 to 4.
33. A vial or ampoule containing a composition according to claim 31 .
34. A vial or ampoule containing a composition according to claim 32 .
35. An aqueous liquid pharmaceutical composition consisting essentially of:
(a) a histone deacetylase (HDAC) inhibitor;
(b) at least one basic in situ salt former, wherein the salt former is free arginine, meglumine or free meglumine, and, (c) a pharmaceutically acceptable excipient or carrier; and
(c) water;
wherein said HDAC inhibitor is:
36. A composition according to claim 35 , which comprises said HDAC inhibitor at a concentration of about 50 mg/mL.
37. A composition according to claim 36 , wherein the molar ratio of said L-arginine to said HDAC inhibitor is from 0.8 to 4.
38. A vial or ampoule containing a composition according to claim 36 .
39. A vial or ampoule containing a composition according to claim 37 .